The NYU Cancer Institute Melanoma Research Program, created in 2002, focuses its research efforts on the development, diagnosis, and treatment of melanoma. The Program includes investigators representing eleven departments of the New York University School of Medicine. 

The mission of the Melanoma Research Program is to:

• Identify risk factors for and prognostic markers of melanoma progression 
• Evaluate the biology of melanoma, including expression and function and molecular alterations of growth control pathways, oncogenes (cancer-promoting genes), and antigens 
• Integrate immunotherapeutic, chemotherapeutic, and biological therapies into combination approaches for treating melanoma 

We have numerous research strengths supporting our Program, including:

• A large population of patients with melanoma 
• A translational research program which drives active research within the program and prospectively accrues melanoma patients' blood, tissue specimens, and clinical information for study
• An immunotherapy program, which evaluates novel cell-based approaches in combination with established or innovative therapies to treat melanoma patients 

In just the first few years of our existence, Program members produced more than 100 melanoma-related publications. The common scientific interests and goals shared by our researchers foster vigorous interactions and collaborations between them. Intra-programmatic collaborations and publications increase yearly. 

Research Areas

The NYU Cancer Institute Melanoma Research Program, created in 2002, focuses its research efforts on the development, diagnosis, and treatment of melanoma.

Major Accomplishments

Recent contributions made by program members

Clinical Trials

Melanoma trials investigating protein expression and treatment outcome, antitumor immunity, cancer drugs for metastatic and locally advanced (stage IV) melanoma, and protein vaccination. Listing of current studies and contact information.

Program Members